New research presented at ASN Kidney Week 2025 (November 5-9) demonstrates that dual inhibition of sodium-glucose cotransporter 1 and 2 (SGLT1/2) provides superior protection against salt-sensitive hypertension and kidney injury compared to selective SGLT2 inhibition alone.
The study, conducted in rat models, reveals that combined SGLT1/2 inhibition with sotagliflozin produces greater reductions in blood pressure and enhanced renal protection than selective SGLT2 inhibition with dapagliflozin.
These findings suggest potential advantages for dual inhibition strategies in managing salt-sensitive hypertension, which affects approximately half of hypertensive patients and contributes significantly to kidney disease progression and cardiovascular complications.
Study Design and Comparative Methodology
Researchers employed a salt-induced hypertension and chronic kidney disease rat model to compare the therapeutic effects of:
- Selective SGLT2 inhibition: Dapagliflozin treatment
- Dual SGLT1/2 inhibition: Sotagliflozin treatment
Both interventions were evaluated under normal salt conditions and high salt challenge, with comprehensive assessment of blood pressure, renal function, metabolic parameters, and histological changes.
Key Findings and Therapeutic Advantages
The investigation revealed several important advantages of dual SGLT1/2 inhibition:
Enhanced blood pressure control: Significantly greater reduction in mean arterial pressure compared to selective SGLT2 inhibition
Superior renal protection: More effective prevention of salt-induced kidney injury
Metabolic benefits: Greater weight reduction and enhanced urinary sodium/chloride excretion
Glucose handling: Near doubling of fractional glucose excretion compared to SGLT2 inhibition alone
Renal safety: Neither treatment adversely affected baseline kidney function
Mechanistic Insights and Pathway Analysis
The study provided novel insights into how SGLT inhibition modulates renal metabolism:
- Region-specific effects: SGLT2 inhibition regulates multiple metabolic pathways in a segment-specific manner
- Lipid metabolism: Significant modulation of lipid handling pathways in renal tissues
- Inflammatory signaling: Notable impact on inflammatory pathways implicated in hypertension progression
“These findings establish a foundation for further investigation of regional renal metabolism,” noted researchers. “They also highlight lipid and inflammatory pathways as promising therapeutic targets for hypertension management.”
Clinical Implications and Future Directions
The research suggests that dual SGLT1/2 inhibition may offer enhanced benefits for patients with salt-sensitive hypertension, particularly those with or at risk for chronic kidney disease. The superior natriuretic and metabolic effects of combined inhibition could address multiple pathological mechanisms in hypertension and renal disease. Future research should focus on:
- Translating these findings to human clinical trials
- Identifying patient subgroups most likely to benefit from dual inhibition
- Exploring optimal dosing strategies for combined SGLT1/2 inhibition
- Investigating long-term cardiovascular and renal outcomes
This research provides important mechanistic evidence supporting the potential advantages of dual SGLT1/2 inhibition over selective SGLT2 inhibition, particularly for the substantial population of patients with salt-sensitive hypertension who face elevated risks of renal and cardiovascular complications.
Related topics
